3. Risk of bias (arranged by intervention).
Name of studies | Intervention 1 | Intervention 2 | Random sequence generation | Allocation concealment | Blinding of participants and health professionals | Blinding of outcome assessors | Attrition bias | Selective outcome reporting | For‐profit bias | Overall risk of bias |
Belli 1998 | Cyclosporine A plus glucocorticosteroids | Cyclosporine A | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Unclear | High |
Pageaux 2004 | Cyclosporine A plus glucocorticosteroids | Cyclosporine A | Unclear | Unclear | Low | Low | Low | Low | High | High |
Masetti 2010 | Everolimus | Cyclosporine A | Unclear | Unclear | High | High | Low | Low | Unclear | High |
Sterneck 2000 | Cyclosporine A plus mycophenolate plus glucocorticosteroids | Cyclosporine A plus azathioprine plus glucocorticosteroids | Unclear | Unclear | Unclear | Unclear | Unclear | Low | High | High |
De Simone 2012 | Tacrolimus plus everolimus | Intervention 1: Everolimus Intervention 2: Tacrolimus |
Unclear | Unclear | High | High | Low | Low | High | High |
Baiocchi 2006 | Cyclosporine A | Tacrolimus | Unclear | Unclear | Unclear | Unclear | Low | High | Unclear | High |
Cholongitas 2011 | Cyclosporine A | Tacrolimus | Low | Low | High | High | Low | Low | Unclear | High |
Fernandez‐Miranda 1998 | Cyclosporine A | Tacrolimus | Unclear | Unclear | Unclear | Unclear | Unclear | High | Unclear | High |
Fung 1991 | Cyclosporine A | Tacrolimus | Low | Low | Unclear | Unclear | Unclear | Low | Low | High |
Greig 2003 | Cyclosporine A | Tacrolimus | Unclear | Unclear | High | High | Low | Low | High | High |
Loinaz 2001 | Cyclosporine A | Tacrolimus | Unclear | Unclear | High | High | Unclear | Low | Unclear | High |
O'Grady 2002 | Cyclosporine A | Tacrolimus | Low | Low | High | High | Low | Low | High | High |
Shenoy 2008 | Cyclosporine A | Tacrolimus | Unclear | Unclear | Unclear | Unclear | Low | Low | High | High |
Stegall 1997 | Cyclosporine A | Tacrolimus | Unclear | Unclear | High | High | Low | Low | Unclear | High |
Zervos 1998 | Cyclosporine A | Tacrolimus | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Unclear | High |
Chen 2002 | Cyclosporine A plus azathioprine | Tacrolimus | Unclear | Unclear | High | High | Low | High | High | High |
Jonas 2005 | Cyclosporine A plus azathioprine | Tacrolimus | Unclear | Unclear | High | High | Low | Low | High | High |
Manousou 2014 | Tacrolimus plus azathioprine | Tacrolimus | Low | Low | Unclear | Unclear | High | Low | High | High |
Boudjema 2011 | Tacrolimus plus mycophenolate plus glucocorticosteroids | Tacrolimus | Low | Low | High | High | Low | Low | Low | High |
Asrani 2014 | Tacrolimus plus sirolimus | Tacrolimus | Low | Unclear | High | High | Low | Low | High | High |
Pham 1998 | Cyclosporine A plus azathioprine plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | Unclear | Unclear | High | High | High | High | Unclear | High |
Porayko 1994 | Cyclosporine A plus azathioprine plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | Unclear | Unclear | High | High | Low | Low | High | High |
Martin 2004 | Cyclosporine A plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | Low | Low | High | High | High | Low | High | High |
Jain 2001 | Tacrolimus plus mycophenolate plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | Low | Low | High | High | Low | Low | Unclear | High |
Fisher 1998 | Cyclosporine A plus mycophenolate | Tacrolimus plus mycophenolate | Unclear | Unclear | High | High | Low | Low | High | High |
Pelletier 2013 | Tacrolimus plus mycophenolate plus glucocorticosteroids | Tacrolimus plus mycophenolate | Unclear | Unclear | High | High | Low | Low | High | High |